Floatz logo

VEMURAFENIB

Hematologic Malignancy

Piramal Enterprises LimitedSmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

43 Active assets in the Hematologic Malignancy cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 2B
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2B
Cytosin-Arabinosid
Senti Biosciences
Phase 2B
Venetoclax
University of Alabama at Birmingham
Phase 2B

View all 50 →

Same molecule, other indications

VEMURAFENIB is also rated in:

melanomaDormant
BB
Indicative ·
66 / 100
View asset →
metastatic melanomaDormant
B
Indicative ·
63 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →